{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Familial+Primary+Pulmonary+Hypertension",
    "query": {
      "condition": "Familial Primary Pulmonary Hypertension"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 41,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Familial+Primary+Pulmonary+Hypertension&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-08T00:20:19.768Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03528902",
      "title": "Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypertension",
        "Pulmonary Arterial Hypertension",
        "Familial Primary Pulmonary Hypertension",
        "Primary Pulmonary Hypertension",
        "Lung Diseases",
        "Tamoxifen",
        "Estrogen Receptor Antagonist",
        "Hormone Antagonists",
        "Estrogens"
      ],
      "interventions": [
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2018-10-01",
      "completion_date": "2023-06-14",
      "has_results": true,
      "last_update_posted_date": "2024-12-05",
      "last_synced_at": "2026-06-08T00:20:19.768Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03528902"
    },
    {
      "nct_id": "NCT03626688",
      "title": "A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "PAH",
        "Pulmonary Hypertension",
        "Pulmonary Arterial Hypertension",
        "Hypertension",
        "Connective Tissue Diseases",
        "Familial Primary Pulmonary Hypertension",
        "Vascular Diseases",
        "Cardiovascular Diseases",
        "Hypertension, Pulmonary",
        "Lung Diseases",
        "Respiratory Tract Disease"
      ],
      "interventions": [
        {
          "name": "Ralinepag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 687,
      "start_date": "2018-08-30",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-06-08T00:20:19.768Z",
      "location_count": 68,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03626688"
    },
    {
      "nct_id": "NCT04084678",
      "title": "A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "PAH",
        "Pulmonary Hypertension",
        "Hypertension",
        "Connective Tissue Disease",
        "Familial Primary Pulmonary Hypertension",
        "Vascular Diseases",
        "Cardiovascular Diseases",
        "Hypertension, Pulmonary",
        "Lung Diseases",
        "Respiratory Tract Disease",
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Ralinepag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2021-01-20",
      "completion_date": "2023-04-12",
      "has_results": false,
      "last_update_posted_date": "2023-10-24",
      "last_synced_at": "2026-06-08T00:20:19.768Z",
      "location_count": 5,
      "location_summary": "Tucson, Arizona • Aurora, Colorado • Denver, Colorado + 2 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04084678"
    },
    {
      "nct_id": "NCT00626028",
      "title": "Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Idiopathic Pulmonary Arterial Hypertension",
        "Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "Nitric Oxide for inhalation",
          "type": "DRUG"
        },
        {
          "name": "Oxygen",
          "type": "DRUG"
        },
        {
          "name": "Nitric Oxide plus Oxygen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Weeks",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "4 Weeks to 18 Years"
      },
      "enrollment_count": 136,
      "start_date": "2004-09",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2019-12-20",
      "last_synced_at": "2026-06-08T00:20:19.768Z",
      "location_count": 8,
      "location_summary": "Stanford, California • Denver, Colorado • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00626028"
    },
    {
      "nct_id": "NCT00759408",
      "title": "The Role of Endothelin in Pulmonary Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "BQ-123",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 38,
      "start_date": "1999-02",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2018-11-27",
      "last_synced_at": "2026-06-08T00:20:19.768Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00759408"
    },
    {
      "nct_id": "NCT03069716",
      "title": "A Mobile Health Intervention in Pulmonary Arterial Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension",
        "Idiopathic Pulmonary Arterial Hypertension",
        "Heritable Pulmonary Arterial Hypertension",
        "Associated Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Smartphone Text Messaging",
          "type": "DEVICE"
        },
        {
          "name": "Fitbit Charge HR",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2017-08-02",
      "completion_date": "2020-04-24",
      "has_results": true,
      "last_update_posted_date": "2021-06-25",
      "last_synced_at": "2026-06-08T00:20:19.768Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03069716"
    },
    {
      "nct_id": "NCT04908397",
      "title": "Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension",
        "Familial Primary Pulmonary Hypertension",
        "Primary Pulmonary Hypertension",
        "Lung Diseases",
        "Carnitine Nutritional Deficiency"
      ],
      "interventions": [
        {
          "name": "L-carnitine",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 10,
      "start_date": "2021-09-29",
      "completion_date": "2023-06-30",
      "has_results": true,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-06-08T00:20:19.768Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04908397"
    },
    {
      "nct_id": "NCT03683186",
      "title": "A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "PAH",
        "Pulmonary Hypertension",
        "Pulmonary Arterial Hypertension",
        "Hypertension",
        "Connective Tissue Diseases",
        "Familial Primary Pulmonary Hypertension",
        "Vascular Diseases",
        "Cardiovascular Diseases",
        "Hypertension, Pulmonary",
        "Lung Diseases",
        "Respiratory Tract Disease"
      ],
      "interventions": [
        {
          "name": "Ralinepag",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2019-09-23",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-20",
      "last_synced_at": "2026-06-08T00:20:19.768Z",
      "location_count": 48,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 38 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03683186"
    },
    {
      "nct_id": "NCT03399604",
      "title": "Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Pulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "LIQ861 Inhaled Treprostinil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Liquidia Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2018-01-02",
      "completion_date": "2019-11-25",
      "has_results": true,
      "last_update_posted_date": "2024-07-30",
      "last_synced_at": "2026-06-08T00:20:19.768Z",
      "location_count": 38,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03399604"
    },
    {
      "nct_id": "NCT03657095",
      "title": "A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Esuberaprost",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lung Biotechnology PBC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 112,
      "start_date": "2018-12-10",
      "completion_date": "2019-07-20",
      "has_results": true,
      "last_update_posted_date": "2020-09-07",
      "last_synced_at": "2026-06-08T00:20:19.768Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03657095"
    }
  ]
}